Patients’ experiences of long-acting injectable antipsychotics: a qualitative study

Código QR

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study

Lin-Ling Chiu,1,* Chun-Hao Liu,2,3,* Chun-Lin Chu,4 Huang-Li Lin,2 Shu-Chung Lii5,*1School of Medicine, Collage of Medicine, Chang Gung University, Taoyuan, Taiwan; 2Department of Psychiatry, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; 3Department of Child Psychiatry, Chang Gun...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chiu LL, Liu CH, Chu CL, Lin HL, Lii SC
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	antipsychotics experience long-acting injectable LAI qualitative research Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/5f8732726d6744c0b49fe565fe0add5c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara N, et al.
Publicado: (2019)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities
por: Junli Zhu, et al.
Publicado: (2021)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
por: Suda A, et al.
Publicado: (2018)

Early Improvement of Psychiatric Symptoms with Long-Acting Injectable Antipsychotic Predicts Subsequent Social Functional Remission in Patients with Schizophrenia
por: Ohnishi T, et al.
Publicado: (2021)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini F, et al.
Publicado: (2019)

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
por: Sajatovic M, et al.
Publicado: (2018)

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
por: Sajatovic M, et al.
Publicado: (2018)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing
por: Lefan Jin, et al.
Publicado: (2021)

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics
por: de Bartolomeis A, et al.
Publicado: (2016)

Discrepancy in Taiwanese psychiatrists’ preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey
por: Liu CH, et al.
Publicado: (2018)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez A, et al.
Publicado: (2019)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
por: Dhiren Singh, et al.
Publicado: (2009)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
por: Natalia N. Petrova, et al.
Publicado: (2020)

Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile
por: Zolezzi M, et al.
Publicado: (2021)

Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
por: Michele Fabrazzo, et al.
Publicado: (2021)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera JJ, et al.
Publicado: (2019)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso C, et al.
Publicado: (2017)

Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole
por: Salzman PM, et al.
Publicado: (2017)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo I, et al.
Publicado: (2018)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury AC, et al.
Publicado: (2021)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
por: Anand E, et al.
Publicado: (2016)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland T, et al.
Publicado: (2019)

Long-acting reversible hormonal contraception
por: N. E. Dahan-Farkas, et al.
Publicado: (2016)

Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
por: Hýža M, et al.
Publicado: (2021)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O'Donnell A, et al.
Publicado: (2021)

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
por: McConnell SA, et al.
Publicado: (2017)

Alcohol dependence is formed on the background of violations of mental adaptation
por: T. V. Agibalova, et al.
Publicado: (2013)

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome L, et al.
Publicado: (2019)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
por: Savitz AJ, et al.
Publicado: (2017)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017)

Users’ Perceptions of an in-Home Electronic Medication Dispensing System: A Qualitative Study
por: Ahmad A, et al.
Publicado: (2020)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao JP, et al.
Publicado: (2017)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si T, et al.
Publicado: (2019)